Please login to the form below

Not currently logged in
Email:
Password:

J&J's profit falls as sales increase

Johnson & Johnson’s third quarter profit for 2011 has fallen 6.3 per cent despite an increase in the US-based pharmaceutical company’s sales performance

Johnson & Johnson's (J&J) third quarter profit for 2011 has fallen 6.3 per cent, with net earnings $3.20bn during the period compared to $3.42bn in 2010.

The dip in profit performance contrasted with the company's sales, which increased by 6.8 per cent to $16.01bn.

However, both the cost of products sold and expenses related to selling, marketing and administration increased significantly between 2010 and 2011 for J&J, with the company also affected by a higher tax rate.

William C Weldon, chairman and CEO of J&J, described the company's performance as “solid” and commended the effect recent product launches have had on revenue.

Regionally, US pharmaceutical sales declined 6.1 per cent, while international sales increased 27.5 per cent to $3.11bn, overtaking the company's revenue in the US.

Sales results in the US were negatively impacted by generic competition for Levaquin (levofloxacin), a treatment for bacterial infections.

A webcast is available concerning J&J's financial results for the third quarter of 2011.

19th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics